236,765 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 236,765 shares of the company's stock, valued at approximately $4,267,000.

Several other hedge funds have also modified their holdings of TEVA. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $30,000. UMB Bank n.a. increased its position in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after buying an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA purchased a new position in Teva Pharmaceutical Industries during the second quarter worth $48,000. Finally, Byrne Asset Management LLC purchased a new position in Teva Pharmaceutical Industries during the second quarter worth $52,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 0.7 %

Shares of NYSE:TEVA traded up $0.13 during midday trading on Tuesday, reaching $18.78. The company's stock had a trading volume of 5,018,319 shares, compared to its average volume of 9,255,074. The business has a 50 day moving average price of $18.03 and a 200 day moving average price of $17.06. Teva Pharmaceutical Industries Limited has a 1 year low of $8.55 and a 1 year high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The firm has a market cap of $21.27 billion, a price-to-earnings ratio of -48.14, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87.

Wall Street Analyst Weigh In

TEVA has been the subject of several recent research reports. UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. Barclays raised their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Finally, Argus raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a research report on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.